Hematopoiesis News Volume 14.49 | Dec 12 2023

    By
    Laurisa Dohm
    -
    0
    10








    2023-12-12 | HN 14.49


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.48 – 12 December, 2023
    TOP STORY

    An IL-4 Signaling Axis in Bone Marrow Drives Pro-Tumorigenic Myelopoiesis

    Using a panel of conditional knockout mice, the authors found that only deletion of the IL-4 receptor IL-4Rα in early myeloid progenitors in bone marrow reduced tumor burden, whereas deletion of IL-4Rα in downstream mature myeloid cells had no effect.
    [Nature]

    AbstractPress Release
    Animal Origin-Free cGMP HSPC Expansion Media
    PUBLICATIONSRanked by the impact factor of the journal

    Immunoproteasome Function Maintains Oncogenic Gene Expression in KMT2A-Complex Driven Leukemia

    Genetic and pharmacologic inactivation of PSMB8 resulted in impaired proliferation of murine and human leukemic cells, while normal hematopoietic cells remained unaffected.
    [Molecular Cancer]

    Full Article

    Duffy Antigen Is Expressed during Erythropoiesis in Duffy-Negative Individuals

    Scientists showed that red blood cells and erythroid progenitors from in vitro differentiated CD34 cells and from bone marrow aspirates from Fy-negative samples expressed a functional Fy on their surface.
    [Cell Host & Microbe]

    AbstractGraphical Abstract

    SON Is an Essential m6A Target for Hematopoietic Stem Cell Fate

    Investigators demonstrated that the nuclear speckle protein SON was an essential m6A target required for murine HSC self-renewal, symmetric commitment, and inflammation control.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    The TLR2/TLR6 Ligand FSL-1 Mitigates Radiation-Induced Hematopoietic Injury in Mice and Nonhuman Primates

    The authors demonstrated that life-threatening hematopoietic injuries in mice and nonhuman primates due to radiation were mitigated with a single subcutaneous administration of the TLR2/TLR6 ligand FSL-1.
    [Proceedings Of The National Academy Of Sciences Of The United States Of America]

    Abstract

    PELI2 Regulates Early B Cell Progenitor Differentiation and Related Leukemia via the IL-7R Expression

    Using a conditional knockout mouse model, researchers demonstrated that PELI2 was required for the early B-cell development and stressed hematopoiesis.
    [Haematologica]

    Abstract

    Co-Targeting HSP90 Alpha and CDK7 Overcomes Resistance against HSP90 Inhibitors in BCR-ABL1+ Leukemia Cells

    Investigators found that the absence of HSP90α caused downregulation of CD45 expression and restricted in vivo growth of BCR-ABL1+ leukemia cells.
    [Cell Death & Disease]

    Full Article

    Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Relapsed or Are Refractory to Erythropoiesis-Stimulating Agents (IMerge): A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase III Trial

    Patients aged ≥18 years with erythropoiesis-stimulating agents (ESA)-relapsed, ESA-refractory, or ESA-ineligible lower-risk myelodysplastic syndromes were randomly assigned via a computer-generated schedule to receive imetelstat 7·5 mg/kg or placebo.
    [Lancet]

    Abstract

    Impact of Central Nervous System Involvement in Adult Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia: A GRAALL-2005 Study

    Between 2006 and 2014, 784 adult patients aged 18-59 years with newly diagnosed Philadelphia-negative acute lymphoblastic leukemia were included, of whom 55 had central nervous system involvement.
    [Haematologica]

    Full Article
    Request a free wallchart with photographs and descriptions of colonies derived from human hematopoietic progenitors.
    REVIEWS

    The Highs and Lows of Cyclic Thrombocytopenia

    While the aetiology of cyclic thrombocytopenia remains uncertain, the authors evaluate historical, theoretical, and clinical findings to provide a framework for understanding cyclic thrombocytopenia pathophysiology.
    [British Journal Of Haematology]

    Abstract
    INDUSTRY AND POLICY NEWS

    FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    The US FDA approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years and older.
    [US FDA]

    Press Release
    FEATURED EVENT

    Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

    February 21 – 24, 2024
    San Antonio, Texas, United States

    > See All Events

    JOB OPPORTUNITIES

    Associate Professor – Pediatric Hematology/Oncology

    Dalhousie University – Halifax, Nova Scotia, Canada

    PhD Positions – Tissue Regeneration and Cancer Immunotherapy

    Albert-Ludwigs-University Freiburg – Freiburg im Breisgau, Germany

    PhD Position – Aging of Human Hematopoietic Stem Cells

    Karolinska Institutet – Flemingsberg, Sweden

    Postdoctoral Associate – Hemostasis and Thromboinflammation in Sickle Cell Disease

    University of Pittsburgh – Pittsburgh, Pennsylvania, United States

    PhD Position – Expanding Blood Stem Cells

    University of York – York, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2